Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 258

1.

How Do Experienced Professors Teach Palliative Medicine in European Universities? A Cross-Case Analysis of Eight Undergraduate Educational Programs.

Noguera A, Bolognesi D, Garralda E, Beccaro M, Kotlinska-Lemieszek A, Furst CJ, Ellershaw J, Elsner F, Csikos A, Filbet M, Biasco G, Centeno C.

J Palliat Med. 2018 Nov;21(11):1621-1626. doi: 10.1089/jpm.2018.0071. Epub 2018 Jul 9.

PMID:
29985742
2.

Recurrent Glioblastoma Treated with Recombinant Poliovirus.

Desjardins A, Gromeier M, Herndon JE 2nd, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD.

N Engl J Med. 2018 Jul 12;379(2):150-161. doi: 10.1056/NEJMoa1716435. Epub 2018 Jun 26.

3.

Towards assessing cortical bone porosity using low-frequency quantitative acoustics: A phantom-based study.

Vogl F, Bernet B, Bolognesi D, Taylor WR.

PLoS One. 2017 Sep 7;12(9):e0182617. doi: 10.1371/journal.pone.0182617. eCollection 2017.

4.

Re: Specialization in palliative medicine for doctors in Europe: an update to 2014.

Bolognesi D, Centeno C, Biasco G.

J Palliat Care. 2015;31(1):63-4. No abstract available.

PMID:
26399094
5.

Comparative analysis of specialization in palliative medicine processes within the World Health Organization European region.

Centeno C, Bolognesi D, Biasco G.

J Pain Symptom Manage. 2015 May;49(5):861-70. doi: 10.1016/j.jpainsymman.2014.10.019. Epub 2015 Jan 24.

6.

The 'surprise' question in advanced cancer patients: A prospective study among general practitioners.

Moroni M, Zocchi D, Bolognesi D, Abernethy A, Rondelli R, Savorani G, Salera M, Dall'Olio FG, Galli G, Biasco G; on behalf of the SUQ-P group.

Palliat Med. 2014 Jul;28(7):959-964. Epub 2014 Mar 24.

PMID:
24662237
7.

A teenager with tetralogy of fallot becomes a soccer player.

Bolognesi M, Bolognesi D.

Am J Case Rep. 2013 Sep 23;14:380-4. doi: 10.12659/AJCR.889440. eCollection 2013.

8.

Acute coronary syndrome vs. myopericarditis - not always a straightforward diagnosis.

Bolognesi M, Bolognesi D.

Am J Case Rep. 2013 Jun 28;14:221-225. Print 2013.

9.

Complicated and delayed diagnosis of tuberculous peritonitis.

Bolognesi M, Bolognesi D.

Am J Case Rep. 2013 Apr 16;14:109-12. doi: 10.12659/AJCR.883886. Print 2013.

10.

Palliative care training and research: the development in europe and the bologna experience.

Bolognesi D, Brighi N, Muciarelli PA, Biasco G.

Indian J Palliat Care. 2013 Jan;19(1):20-6. doi: 10.4103/0973-1075.110221.

11.

Right Ventricular Overload Due to Severe Pulmonary Valve Regurgitation in 44-Year-Old GUCH.

Bolognesi M, Bolognesi D.

J Cardiovasc Echogr. 2013 Apr-Jun;23(2):69-71. doi: 10.4103/2211-4122.123037.

12.
13.

Investment of palliative medicine in bridging the gap with academia: a call to action.

Moroni M, Bolognesi D, Muciarelli PA, Abernethy AP, Biasco G.

Eur J Cancer. 2011 Mar;47(4):491-5. doi: 10.1016/j.ejca.2010.12.014. Epub 2011 Jan 17.

PMID:
21247756
14.

Heterobiaryl human immunodeficiency virus entry inhibitors.

Lu RJ, Tucker JA, Pickens J, Ma YA, Zinevitch T, Kirichenko O, Konoplev V, Kuznetsova S, Sviridov S, Brahmachary E, Khasanov A, Mikel C, Yang Y, Liu C, Wang J, Freel S, Fisher S, Sullivan A, Zhou J, Stanfield-Oakley S, Baker B, Sailstad J, Greenberg M, Bolognesi D, Bray B, Koszalka B, Jeffs P, Jeffries C, Chucholowski A, Sexton C.

J Med Chem. 2009 Jul 23;52(14):4481-7. doi: 10.1021/jm900330x.

PMID:
19534463
15.

Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide group.

Lu RJ, Tucker JA, Zinevitch T, Kirichenko O, Konoplev V, Kuznetsova S, Sviridov S, Pickens J, Tandel S, Brahmachary E, Yang Y, Wang J, Freel S, Fisher S, Sullivan A, Zhou J, Stanfield-Oakley S, Greenberg M, Bolognesi D, Bray B, Koszalka B, Jeffs P, Khasanov A, Ma YA, Jeffries C, Liu C, Proskurina T, Zhu T, Chucholowski A, Li R, Sexton C.

J Med Chem. 2007 Dec 27;50(26):6535-44. Epub 2007 Dec 4.

PMID:
18052117
16.

How to identify and calculate glenoid bone deficit.

Baudi P, Righi P, Bolognesi D, Rivetta S, Rossi Urtoler E, Guicciardi N, Carrara M.

Chir Organi Mov. 2005 Apr-Jun;90(2):145-52. English, Italian.

PMID:
16422240
17.

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.

Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, Bolognesi D.

Nat Rev Drug Discov. 2004 Mar;3(3):215-25. Review.

PMID:
15031735
18.

Basic science in a department of surgery.

Bolognesi DP.

Ann Surg. 2003 Dec;238(6 Suppl):S33. No abstract available.

PMID:
14703742
19.

HIV fusion and its inhibition.

LaBranche CC, Galasso G, Moore JP, Bolognesi DP, Hirsch MS, Hammer SM.

Antiviral Res. 2001 May;50(2):95-115. Review. No abstract available.

PMID:
11369431
20.

Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41.

Chen CH, Greenberg ML, Bolognesi DP, Matthews TJ.

AIDS Res Hum Retroviruses. 2000 Dec 10;16(18):2037-41.

PMID:
11153086
21.

A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group.

McElrath MJ, Corey L, Montefiori D, Wolff M, Schwartz D, Keefer M, Belshe R, Graham BS, Matthews T, Wright P, Gorse G, Dolin R, Berman P, Francis D, Duliege AM, Bolognesi D, Stablein D, Ketter N, Fast P.

AIDS Res Hum Retroviruses. 2000 Jun 10;16(9):907-19.

PMID:
10875616
22.

Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection.

Markert ML, Hicks CB, Bartlett JA, Harmon JL, Hale LP, Greenberg ML, Ferrari G, Ottinger J, Boeck A, Kloster AL, McLaughlin TM, Bleich KB, Ungerleider RM, Lyerly HK, Wilkinson WE, Rousseau FS, Heath-Chiozzi ME, Leonard JM, Haase AT, Shaw GM, Bucy RP, Douek DC, Koup RA, Haynes BF, Bolognesi DP, Weinhold KJ.

AIDS Res Hum Retroviruses. 2000 Mar 20;16(5):403-13.

PMID:
10772526
23.

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.

Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS.

Nat Med. 1998 Nov;4(11):1302-7.

PMID:
9809555
24.

Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: a potential strategy for reduction of virus-infected cellular reservoirs.

Tyler DS, Stanley SD, Bartlett JA, Bolognesi DP, Weinhold KJ.

J Surg Res. 1998 Oct;79(2):115-20.

PMID:
9758725
25.

Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus.

Langlois AJ, Desrosiers RC, Lewis MG, KewalRamani VN, Littman DR, Zhou JY, Manson K, Wyand MS, Bolognesi DP, Montefiori DC.

J Virol. 1998 Aug;72(8):6950-5.

27.

Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage.

Montefiori DC, Collman RG, Fouts TR, Zhou JY, Bilska M, Hoxie JA, Moore JP, Bolognesi DP.

J Virol. 1998 Mar;72(3):1886-93.

28.

HIV vaccines. Viral envelope fails to deliver?

Bolognesi DP, Matthews TJ.

Nature. 1998 Feb 12;391(6668):638-9. No abstract available.

PMID:
9490406
29.

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.

Pilgrim AK, Pantaleo G, Cohen OJ, Fink LM, Zhou JY, Zhou JT, Bolognesi DP, Fauci AS, Montefiori DC.

J Infect Dis. 1997 Oct;176(4):924-32.

PMID:
9333150
30.

HIV. A clever hijacker of the immune system.

Bolognesi DP.

Curr Opin Immunol. 1997 Aug;9(4):549-50. No abstract available.

PMID:
9287181
31.

Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers.

Ferrari G, Humphrey W, McElrath MJ, Excler JL, Duliege AM, Clements ML, Corey LC, Bolognesi DP, Weinhold KJ.

Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1396-401.

32.

Noncytolytic CD8 T cell-mediated suppression of HIV replication.

Greenberg ML, Lacey SF, Chen CH, Bolognesi DP, Weinhold KJ.

Springer Semin Immunopathol. 1997;18(3):355-69. Review. No abstract available.

PMID:
9089954
33.

Overview of HIV vaccine development.

Bolognesi DP.

Antibiot Chemother (1971). 1996;48:63-7. Review. No abstract available.

PMID:
8726507
34.

IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp).

Ferrari G, King K, Rathbun K, Place CA, Packard MV, Bartlett JA, Bolognesi DP, Weinhold KJ.

Clin Exp Immunol. 1995 Aug;101(2):239-48.

35.

Immunodeficiency.

Bolognesi DP, Cooper MD.

Curr Opin Immunol. 1995 Aug;7(4):433-5. Review. No abstract available.

PMID:
7495504
36.
37.

Multiple CTL specificities against autologous HIV-1-infected BLCLs.

Ahearne PM, Morgan RA, Sebastian MW, Bolognesi DP, Weinhold KJ.

Cell Immunol. 1995 Mar;161(1):34-41.

PMID:
7867083
38.

Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.

Keefer MC, Graham BS, Belshe RB, Schwartz D, Corey L, Bolognesi DP, Stablein DM, Montefiori DC, McElrath MJ, Clements ML, et al.

AIDS Res Hum Retroviruses. 1994 Dec;10(12):1713-23.

PMID:
7888231
39.

NIH conference. HIV vaccine development: a progress report.

Hoth DF, Bolognesi DP, Corey L, Vermund SH.

Ann Intern Med. 1994 Oct 15;121(8):603-11. Review.

PMID:
8085693
40.

HIV infection in vaccinated volunteers.

Belshe RB, Bolognesi DP, Clements ML, Corey L, Dolin R, Mestecky J, Mulligan M, Stablein D, Wright P.

JAMA. 1994 Aug 10;272(6):431. No abstract available.

PMID:
8040971
41.

Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.

Belshe RB, Graham BS, Keefer MC, Gorse GJ, Wright P, Dolin R, Matthews T, Weinhold K, Bolognesi DP, Sposto R, et al.

JAMA. 1994 Aug 10;272(6):475-80.

PMID:
7913731
42.

Immunodeficiency.

Cooper MD, Bolognesi DP.

Curr Opin Immunol. 1994 Aug;6(4):597-9. Review. No abstract available.

PMID:
7946048
43.

Structural rearrangements in the transmembrane glycoprotein after receptor binding.

Matthews TJ, Wild C, Chen CH, Bolognesi DP, Greenberg ML.

Immunol Rev. 1994 Aug;140:93-104. Review. No abstract available.

PMID:
7821930
44.

Comparison of anti-HIV-1 ADCC reactivities in infected humans and chimpanzees.

Ferrari G, Place CA, Ahearne PM, Nigida SM Jr, Arthur LO, Bolognesi DP, Weinhold KJ.

J Acquir Immune Defic Syndr. 1994 Apr;7(4):325-31.

PMID:
8133445
45.

Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein.

Javaherian K, Langlois AJ, Montefiori DC, Kent KA, Ryan KA, Wyman PD, Stott J, Bolognesi DP, Murphey-Corb M, Larosa GJ.

J Virol. 1994 Apr;68(4):2624-31.

46.

CD8+ T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism.

Chen CH, Weinhold KJ, Bartlett JA, Bolognesi DP, Greenberg ML.

AIDS Res Hum Retroviruses. 1993 Nov;9(11):1079-86.

PMID:
8312050
47.

Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.

Haynes BF, Torres JV, Langlois AJ, Bolognesi DP, Gardner MB, Palker TJ, Scearce RM, Jones DM, Moody MA, McDanal C, et al.

J Immunol. 1993 Aug 1;151(3):1646-53.

PMID:
8335949
48.

The immune response to HIV: implications for vaccine development.

Bolognesi DP.

Semin Immunol. 1993 Jun;5(3):203-14. Review.

PMID:
8347841
49.

AIDS. Where has HIV been hiding?

Temin HM, Bolognesi DP.

Nature. 1993 Mar 25;362(6418):292-3. No abstract available.

PMID:
8455713
50.

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.

Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF, Gorse GJ, Schwartz DH, Keefer MC, Bolognesi DP, et al.

J Infect Dis. 1993 Mar;167(3):533-7.

PMID:
8095059

Supplemental Content

Loading ...
Support Center